| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7230c2b91e3b4d3f30765f811e86acbc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_add256894a7a94b02eb11d5fd4f1e3dc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d0af152b45d13e721f5cd3557db62d98
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_253701b0ddf76be52966cb59eb29a77c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c9ce5c78f1e303770ae744763b95142f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2014-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e54151f72c3745abf435bdcf488de147
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f84d72a6203db05d06208dcf733c5016
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d922532868d958ee6c2cee0fcfea799d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_36cf7d6238b8bfda25ca5e3e7fd3b7ad
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6c87ae26aed22f53bd0bc1eccf68990b |
| publicationDate |
2014-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2014191938-A1 |
| titleOfInvention |
Combination therapy containing a pi3k-alpha inhibitor and fgfr kinase inhibitor for treating cancer |
| abstract |
A pharmaceutical combination comprising an alpha-isoform specific phosphatidylinositol 3-kinase inhibitor compound of formula (I) or a pharmaceutically acceptable salt thereof and a fibroblast growth factor receptor (FGFR) kinase inhibitor, particularly for simultaneous, separate or sequential use for the treatment of a cancer; use of such pharmaceutical combination for the preparation of a medicament for the treatment of a cancer; use of such pharmaceutical combination for the treatment a cancer; a method for treating a cancer comprising administering to a subject having said cancer a jointly therapeutically effective amount of such combination; and related pharmaceutical compositions or kits thereof. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-2552267-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-2552267-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113930507-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016142312-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016142313-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016109452-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2018510869-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107683138-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107406876-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107406876-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107864625-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10406162-B2 |
| priorityDate |
2013-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |